N/A N=303 The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes
Tuberculosis · Alcohol Consumption · Treatment Adverse Effect
Primary: Time to Culture Conversion — 5.6; 5.4; 5.5 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=201 Risk of Oxygen During Cardiac Surgery Trial
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
N/A N=14 Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes
Diabetes Mellitus, Type 1 · Autoimmune Diseases · Diabetes Mellitus
Primary: HbA1c, Glycated Hemoglobin — 7.9; 8.3; 8.0; 8.4 percentage of total hemoglobin
N/A N=1,010 Primary Care Pediatrics Learning Activity and Nutrition With Families
Pediatric Obesity
Primary: Body Composition Measures of Targeted Child. Percent Change Over the Median BMI — 10.2; 3.4 percent change — p=<0.05
Phase 2 N=220 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
Crohn's Disease
Primary: Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 — 0; 10.3; 8.1; 8.3 percentage of participants — p=0.056
Phase 3 N=107 Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Facial Angiofibroma · Tuberous Sclerosis
Primary: Percentage of Participants Obtaining Successful Treatment — 4; 3; 2 Participants
N/A N=28 Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) · Breast Cancer
Primary: Oxylipin Levels — 10.2; 12.1; 12.3 pg/mL — p=0.684
Phase 4 N=60 Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 54.30; 90.85; 72.53; 76.05 Score on a 100 mm scale — p=<0.0001
N/A N=12 Adaptation of the Friendship Bench Intervention for HIV-infected Perinatal Women in Lilongwe
Human Immunodeficiency Virus · Perinatal Depression
Primary: Intervention Feasibility- Number of Participants Enrolled in Each Arm — 5; 43; 44 Participants
N/A N=81 Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses
Autism Spectrum Disorder
Primary: ABR Peak V Latency — 6; 5.8; 6.29; 5.99 ms
Phase 4 N=70 Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension
Hypertension in Pregnancy · Postpartum Preeclampsia
Primary: Number of Participants With Stage 2 Hypertension — 8; 12 Participants
Phase 4 N=54 Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
Abuse Potential
Primary: Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax). — 54.89; 87.40; 57.89; 63.62 Score on a 100 mm scale — p=<.0001
Phase 2 N=90 A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
Chronic Plaque-type Psoriasis
Primary: Proportion of Patients Achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% Reduction From Baseline PASI Score). (Scores Range From 0 (Minimum) to 30…
Phase 3 N=75 Testopel ® vs. Generic Testosterone Pellets.
Hypogonadism
Primary: Change in Testosterone (T) Levels — 219.5; 202.3; 543; 696.5 ng/dL
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants